Cognitive Behavioural Suicide Prevention for psychosis
ISRCTN | ISRCTN16939126 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN16939126 |
Secondary identifying numbers | 6329 |
- Submission date
- 21/05/2010
- Registration date
- 21/05/2010
- Last edited
- 09/09/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Nick Tarrier
Scientific
Scientific
Zochonis Building
Brunswick Street
Oxford Road
Manchester
M13 9PL
United Kingdom
Phone | +44 161 306 6000 |
---|---|
nicholas.tarrier@manchester.ac.uk |
Study information
Study design | Multicentre randomised interventional treatment trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Other |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Prevention of Suicide risk in patients with psychosis through the development of a focused and conceptually-driven intervention |
Study acronym | CBSPp |
Study objectives | Study aims: 1. To confirm and describe the psychological architecture that drives suicide behaviour, this consists of: information processing biases, suicide schema and appraisal systems. We intend to investigate hypotheses relating to determine the role of these in suicide behaviour specifically we will use information processing tasks such as autobiographical memory tasks to investigate bias; standardised assessment to investigate appraisal and schema. 2. To derive a method of assessing this architecture through semi-structured interview that will have clinical utility 3. To formulate and develop a manualised cognitive behavioural treatment programme for suicide prevention in psychosis and to test the clinical acceptance and feasibility of this intervention. It is hypothesised that the treatment will be acceptable, feasible and reduce suicide behaviour. 4. At the end of the programme we will be in position to design a clinical trial to test the efficacy of the intervention |
Ethics approval(s) | Stockport REC , 12/12/2008, ref: 08/H1012/97 |
Health condition(s) or problem(s) studied | Topic: Mental Health Research Network; Subtopic: Psychosis; Disease: Psychosis |
Intervention | Those allocated to the experimental treatment will receive CBSPp as described in the manual in addition to treatment as usual (TAU). Treatment will take place over 12 weeks. Participants will be seen twice weekly. The control group will receive TAU alone. All participants will be re-assessed at 4 months and at 6 months. Study entry: single randomisation only |
Intervention type | Other |
Primary outcome measure | Suicidal behaviour, measured at 4 months and 6 months |
Secondary outcome measures | Measured at baseline, 4 months and 6 months: 1. Beck Anxiety Inventory (BAI) to assess level of anxiety 2. Beck Hopelessness Scale 3. Calagary Depression Scale for Schizophrenia 4. Global assessment of functioning (DSM-IV) to assess overall functioning 5. Positive And Negative Symptoms Scale (PANSS) to assess severity of symptoms 6. Psychotic Symptom Rating Scales (PSYRATS) to assess control over symptoms 7. Questionnaire about the Process of Recovery (QPR) 8. Self Esteem Rating Scale 9. The Subjective Experiences of Psychotic Symptoms Scale (SEPSS) |
Overall study start date | 01/02/2009 |
Completion date | 31/12/2010 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | Planned sample size: 60; UK sample size: 60 |
Key inclusion criteria | 1. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder or psychotic disorder not otherwise specified (NOS) 2. Have had previous suicide attempts or current suicidal ideation 3. Are not currently acutely suicidal or considered a danger to themselves or others 4. Are receiving appropriate anti-psychotic medication 5. Are under the care of an appropriate clinical team and have contact with mental health service 6. Males and females aged between 18 and 65 years |
Key exclusion criteria | Not providing informed consent |
Date of first enrolment | 01/02/2009 |
Date of final enrolment | 31/12/2010 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Zochonis Building
Manchester
M13 9PL
United Kingdom
M13 9PL
United Kingdom
Sponsor information
University of Manchester (UK)
University/education
University/education
Oxford Road
Manchester
M13 9PL
England
United Kingdom
Website | http://www.manchester.ac.uk/ |
---|---|
https://ror.org/027m9bs27 |
Funders
Funder type
Government
National Insititute for Health Research (NIHR) (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Editorial Notes
09/09/2016: No publications found in PubMed, verifying study status with principal investigator.